Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis
- 14 April 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 72 (15), 1322-1329
- https://doi.org/10.1212/wnl.0b013e3181a0fe3f
Abstract
Objective: Axonal degeneration is the likely cause of disease progression in multiple sclerosis (MS). Our previous results indicated that neuron-specific N-acetylaspartate (NAA) is a candidate CSF biomarker for disease progression in MS. The aim of this study was to explore the potential of NAA as an early biomarker of axonal damage in MS. Next, we wanted to know the additional value of measurement of NAA compared to other candidate markers for axonal damage, such as neurofilament subunits and tau protein. Methods: Levels of NAA, neurofilament light, neurofilament heavy, and tau were determined in CSF of patients with clinically isolated syndrome (CIS, n = 38), relapsing-remitting MS (RRMS, n = 42), secondary progressive MS (SPMS, n = 28), and primary progressive MS (PPMS, n = 6); patients without neurologic disease (ND, n = 28); noninflammatory neurologic controls (n = 18); and inflammatory neurologic controls (n = 39). Results: CSF NAA levels were decreased in patients with SPMS compared to ND controls, patients with CIS, and patients with RRMS. CSF NAA levels in patients with CIS and RRMS were similar to those in ND subjects. All axonal damage proteins showed specific patterns of changes and relations with disease activity measures. The neurofilament light chain levels were already increased in patients with CIS, especially in patients who converted to MS. The neurofilament heavy chain levels were highest in the patients with SPMS. Tau levels were similar in MS and ND. Conclusions: CSF N-acetylaspartate (NAA) levels were not different from patients without neurologic disease in early stages of multiple sclerosis, though decreased as the disease progressed. Combining CSF NAA and neurofilament levels yields information on different phases of axonal pathology.Keywords
This publication has 26 references indexed in Scilit:
- Cerebrospinal fluid total tau protein levels in patients with multiple sclerosisActa Neurologica Scandinavica, 2007
- N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometryZeitschrift für Neurologie, 2007
- Sodium Channels and Multiple Sclerosis: Roles in Symptom Production, Damage and TherapyBrain Pathology, 2007
- I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophyMultiple Sclerosis Journal, 2007
- N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiologyProgress in Neurobiology, 2007
- Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patientsAnnals of Neurology, 2006
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Stable isotope dilution analysis ofN‐acetylaspartic acid in CSF, blood, urine and amniotic fluid: Accurate postnatal diagnosis and the potential for prenatal diagnosis of canavan diseaseJournal of Inherited Metabolic Disease, 1990